

Raptor Pharmaceutical Corp  
Form 4  
October 03, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Hyperion Trading Segregated Portfolio

(Last) (First) (Middle)

C/O TMF LTD. GRAND PAVILLION COMM. CTR, 2ND FL., 802 WEST BAY ROAD, PO BOX 10338

(Street)

GRAND CAYMAN, E9 KY1-1003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Raptor Pharmaceutical Corp [RPTP]

3. Date of Earliest Transaction  
(Month/Day/Year)  
01/02/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value \$0.001 per share (1) (2)	01/02/2013		P		11,500	A	\$ 5.89 (3)
Common Stock, par value \$0.001 per share (1) (2)	01/02/2013		S		7,182	D	\$ 5.98 (4)

Edgar Filing: Raptor Pharmaceutical Corp - Form 4

Common Stock, par value	01/03/2013	S	5,568	D	\$ 6.06 <u>(5)</u>	6,441,435	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	01/04/2013	S	4,700	D	\$ 6.1 <u>(6)</u>	6,436,735	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	01/07/2013	S	1,800	D	\$ 6.26	6,434,935	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	01/07/2013	P	21,800	A	\$ 6.16 <u>(7)</u>	6,456,735	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	01/08/2013	P	23,977	A	\$ 6.19 <u>(8)</u>	6,480,712	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	01/09/2013	P	56,352	A	\$ 6.13 <u>(9)</u>	6,537,064	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	01/16/2013	S	4,400	D	\$ 5.91 <u>(10)</u>	6,532,664	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	01/16/2013	P	2,000	A	\$ 5.75 <u>(11)</u>	6,534,664	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	01/17/2013	P	7,000	A	\$ 5.75 <u>(12)</u>	6,541,664	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
	01/22/2013	P	3,000	A		6,544,664	D

Edgar Filing: Raptor Pharmaceutical Corp - Form 4

Common Stock, par value \$0.001 per share <u>(1)</u> <u>(2)</u>					\$ 5.7 <u>(13)</u>		
Common Stock, par value \$0.001 per share <u>(1)</u> <u>(2)</u>	01/28/2013	P	24,500	A	\$ 5.45 <u>(14)</u>	6,569,164	D
Common Stock, par value \$0.001 per share <u>(1)</u> <u>(2)</u>	01/29/2013	P	98,818	A	\$ 5.42 <u>(15)</u>	6,667,982	D
Common Stock, par value \$0.001 per share <u>(1)</u> <u>(2)</u>	01/30/2013	P	69,455	A	\$ 5.41 <u>(16)</u>	6,737,437	D
Common Stock, par value \$0.001 per share <u>(1)</u> <u>(2)</u>	02/01/2013	P	59,910	A	\$ 5.49 <u>(17)</u>	6,797,347	D
Common Stock, par value \$0.001 per share <u>(1)</u> <u>(2)</u>	02/05/2013	P	26,000	A	\$ 5.42 <u>(18)</u>	6,823,347	D
Common Stock, par value \$0.001 per share <u>(1)</u> <u>(2)</u>	02/08/2013	P	97,500	A	\$ 5.18 <u>(19)</u>	6,920,847	D
Common Stock, par value \$0.001 per share <u>(1)</u> <u>(2)</u>	02/25/2013	S	5,250	D	\$ 5.25 <u>(20)</u>	6,915,597	D
Common Stock, par value \$0.001 per share <u>(1)</u> <u>(2)</u>	03/08/2013	S	1,750	D	\$ 5.34	6,913,847	D
	03/11/2013	S	10,000	D		6,903,847	D

Edgar Filing: Raptor Pharmaceutical Corp - Form 4

Common Stock, par value					\$ 5.47 <u>(21)</u>		
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	03/15/2013	S	4,300	D	\$ 5.98 <u>(22)</u>	6,899,547	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	03/22/2013	S	47,777	D	\$ 5.6 <u>(23)</u>	6,851,770	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	03/26/2013	S	50,678	D	\$ 5.65 <u>(24)</u>	6,801,092	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	03/27/2013	S	19,160	D	\$ 5.71 <u>(25)</u>	6,781,932	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	04/04/2013	S	9,746	D	\$ 6 <u>(26)</u>	6,772,186	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							
Common Stock, par value	04/05/2013	S	71,650	D	\$ 5.95 <u>(27)</u>	6,700,536	D
\$0.001 per share <u>(1)</u> <u>(2)</u>							

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying	8. Price of Derivative Security	9. Nu Deriv Secur
---------------------------------------	------------------------------	---	---	------------------------	-----------------	--	---	---------------------------------------	-------------------------

Edgar Filing: Raptor Pharmaceutical Corp - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Securities (Instr. 3 and 4)	(Instr. 5)	Bene- ficial Own- er Follo- wing Repo- sition Trans- (Instr.			
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director    10% Owner    Officer    Other

Hyperion Trading Segregated Portfolio  
C/O TMF LTD. GRAND PAVILLION COMM. CTR  
2ND FL., 802 WEST BAY ROAD, PO BOX 10338  
GRAND CAYMAN, E9 KY1-1003

X

## Signatures

/s/ David P.M. Blair and Richard A.  
Reinert

08/19/2014

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of common stock, \$0.001 par value per share (the "Common Shares"), of Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), reported herein were held by Hyperion Trading Segregated Portfolio (the "Reporting Person"), a segregated portfolio of Strategic Investment Tribes Fund SPC, a Cayman Islands exempted company registered as a segregated portfolio company, managed by Sequoia Asset Management S.A., a company organized under the laws of Switzerland ("Sequoia").
- (2) The Common Shares reported herein represent transactions undertaken by the Reporting Person. Pursuant to Reg. Section 240.16a-1(a)(1), Sequoia, as the investment manager of the Reporting Person, is not deemed a beneficial owner of the Common Shares held by the Reporting Person or any other account managed by Sequoia. In the event that Sequoia is deemed a beneficial owner of the Common Shares held by the Reporting Person or any other account managed by Sequoia, pursuant to Reg. Section 240.16a-1(a)(2), its beneficial ownership is limited to its pecuniary interest, if any, in such Common Shares.
- (3) This price represents the weighted average purchase price of the Common Shares on January 2, 2013, which were purchased in multiple transactions ranging from \$5.87 to \$5.93, inclusive.
- (4) This price represents the weighted average sale price of the Common Shares on January 2, 2013, which were sold in multiple transactions ranging from \$5.95 to \$5.99, inclusive.
- (5) This price represents the weighted average sale price of the Common Shares on January 3, 2013, which were sold in multiple transactions ranging from \$6.06 to \$6.06, inclusive.
- (6) This price represents the weighted average sale price of the Common Shares on January 4, 2013, which were sold in multiple transactions ranging from \$6.07 to \$6.15, inclusive.
- (7) This price represents the weighted average purchase price of the Common Shares on January 7, 2013, which were purchased in multiple transactions ranging from \$6.15 to \$6.17, inclusive.

## Edgar Filing: Raptor Pharmaceutical Corp - Form 4

- (8) This price represents the weighted average purchase price of the Common Shares on January 8, 2013, which were purchased in multiple transactions ranging from \$6.16 to \$6.24, inclusive.
- (9) This price represents the weighted average purchase price of the Common Shares on January 9, 2013, which were purchased in multiple transactions ranging from \$6.08 to \$6.21, inclusive.
- (10) This price represents the weighted average sale price of the Common Shares on January 16, 2013, which were sold in multiple transactions ranging from \$5.90 to \$5.93, inclusive.
- (11) This price represents the weighted average purchase price of the Common Shares on January 16, 2013, which were purchased in multiple transactions ranging from \$5.75 to \$5.76, inclusive.
- (12) This price represents the weighted average purchase price of the Common Shares on January 17, 2013, which were purchased in multiple transactions ranging from \$5.74 to \$5.75, inclusive.
- (13) This price represents the weighted average purchase price of the Common Shares on January 22, 2013, which were purchased in multiple transactions ranging from \$5.69 to \$5.70, inclusive.
- (14) This price represents the weighted average purchase price of the Common Shares on January 28, 2013, which were purchased in multiple transactions ranging from \$5.42 to \$5.47, inclusive.
- (15) This price represents the weighted average purchase price of the Common Shares on January 29, 2013, which were purchased in multiple transactions ranging from \$5.38 to \$5.46, inclusive.
- (16) This price represents the weighted average purchase price of the Common Shares on January 30, 2013, which were purchased in multiple transactions ranging from \$5.37 to \$5.42, inclusive.
- (17) This price represents the weighted average purchase price of the Common Shares on February 1, 2013, which were purchased in multiple transactions ranging from \$5.45 to \$5.50, inclusive.
- (18) This price represents the weighted average purchase price of the Common Shares on February 5, 2013, which were purchased in multiple transactions ranging from \$5.38 to \$5.49, inclusive.
- (19) This price represents the weighted average purchase price of the Common Shares on February 8, 2013, which were purchased in multiple transactions ranging from \$5.16 to \$5.21, inclusive.
- (20) This price represents the weighted average sale of the Common Shares on February 25, 2013, which were sold in multiple transactions ranging from \$5.20 to \$5.29, inclusive.
- (21) This price represents the weighted average sale of the Common Shares on March 11, 2013, which were sold in multiple transactions ranging from \$5.39 to \$5.50, inclusive.
- (22) This price represents the weighted average sale of the Common Shares on March 15, 2013, which were sold in multiple transactions ranging from \$5.96 to \$5.99, inclusive.
- (23) This price represents the weighted average sale of the Common Shares on March 22, 2013, which were sold in multiple transactions ranging from \$5.53 to \$5.75, inclusive.
- (24) This price represents the weighted average sale of the Common Shares on March 26, 2013, which were sold in multiple transactions ranging from \$5.58 to \$5.70, inclusive.
- (25) This price represents the weighted average sale of the Common Shares on March 27, 2013, which were sold in multiple transactions ranging from \$5.70 to \$5.72, inclusive.
- (26) This price represents the weighted average sale of the Common Shares on April 4, 2013, which were sold in multiple transactions ranging from \$5.98 to \$6.04, inclusive.
- (27) This price represents the weighted average sale of the Common Shares on April 5, 2013, which were sold in multiple transactions ranging from \$5.90 to \$6.08, inclusive.

### Remarks:

1. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the Staff of the Security

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.